ECM
AIMT

ExodusPoint Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

ExodusPoint Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13,307
Closed -$279K – 2043
2019
Q3 		$279K Buy
+13,307
New +$272K 0.01% 927

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ExodusPoint Capital Management's AIMT Position: Q4 2019 in Review

ExodusPoint Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 13,307 shares — an estimated $279K sold.

ExodusPoint Capital Management first reported a position in AIMT in Q3 2019 and held it in 1 quarter. The position peaked at $279K in Q3 2019. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • ExodusPoint Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • ExodusPoint Capital Management sold 13,307 Aimmune Therapeutics shares in Q4 2019, an estimated $279K.
  • ExodusPoint Capital Management first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 1 quarter.
  • ExodusPoint Capital Management's Aimmune Therapeutics position peaked at $279K in Q3 2019.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on ExodusPoint Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.